Enemali et al., 2015 - Google Patents
Effect of monosodium glutamate orally administered to male wister rats on some biochemical parametersEnemali et al., 2015
View PDF- Document ID
- 12507562430273085219
- Author
- Enemali M
- Danielson E
- Bamidele T
- Publication year
- Publication venue
- J. Biol Agric Healthcare
External Links
Snippet
Monosodium glutamate (MSG) of brand name “Ajinomoto” was purchased from Nsukka Market and was administered to wistar rat. Twenty four wistar rats were randomly divided into four groups housed in different cages. The rats were administered with varying doses …
- 235000013923 monosodium glutamate 0 title abstract description 69
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Souza et al. | The integral role of magnesium in muscle integrity and aging: a comprehensive review | |
| Papadopoulou | Rehabilitation nutrition for injury recovery of athletes: the role of macronutrient intake | |
| Pickering et al. | Magnesium status and stress: the vicious circle concept revisited | |
| Brancaccio et al. | The biological role of vitamins in athletes’ muscle, heart and microbiota | |
| Uysal et al. | Timeline (bioavailability) of magnesium compounds in hours: which magnesium compound works best? | |
| Baryshev et al. | New methods for detoxification of heavy metals and mycotoxins in dairy cows | |
| Stanstrup et al. | Whey protein delays gastric emptying and suppresses plasma fatty acids and their metabolites compared to casein, gluten, and fish protein | |
| Mardinoglu et al. | The potential use of metabolic cofactors in treatment of NAFLD | |
| Rasmussen et al. | Determination of the safety of leucine supplementation in healthy elderly men | |
| Holeček | Branched-chain amino acids and branched-chain keto acids in hyperammonemic states: metabolism and as supplements | |
| Adamolekun | Neurological disorders associated with cassava diet: a review of putative etiological mechanisms | |
| WO2016179657A1 (en) | Amino acid supplementation | |
| Cordeiro et al. | Effects of fish protein hydrolysate ingestion on postexercise aminoacidemia compared with whey protein hydrolysate in young individuals | |
| Enemali et al. | Effect of monosodium glutamate orally administered to male wister rats on some biochemical parameters | |
| RU2506084C1 (en) | Drug preparation for prevention and treatment of hypovitaminosis and normalisation of metabolism in poultry | |
| US20160158309A1 (en) | Exercise function enhancer | |
| Płoszczyca et al. | Effects of short-term phosphate loading on aerobic capacity under acute hypoxia in cyclists: a randomized, placebo-controlled, crossover study | |
| Noor et al. | The seluang fish (Rasbora spp.) diet to improve neurotoxicity of endosulfan-induced intrauterine pup's brain through of oxidative mechanism | |
| Schmid | The most common poisons for pets | |
| RU2659127C1 (en) | Method of increasing osmotic resistance of erythrocyte membranes | |
| RU2735863C1 (en) | Composition for preventing and treating stress in dogs and cats of exogenous aetiology | |
| Camenzuli | Effect of acute exercise on muscle and liver glucose metabolism in T1DM rodents | |
| Fukui et al. | Effects of deep-sea water on training efficiency, locomotor function and respiratory metabolism in young and aged mice | |
| EP2388011B1 (en) | Antioxidant composition for reducing oxidative stress in dogs | |
| RU2701503C1 (en) | Medicinal agent for normalizing metabolic processes in animals |